An oral drug that blocks the interleukin-23 (IL-23) receptor, already approved for psoriasis, produced lasting clinical responses and remission in patients with moderate to severe ulcerative colitis (UC), with symptom improvement continuing well past week 12, according to findings presented at the American College of Gastroenterology’s 2026 Annual Scientific Meeting in Nashville, Tennessee.
At week 76, 73% to 81% of the 136 patients in the long-term extension of the phase 2b ANTHEM-UC trial of icotrokinra were in clinical response, and 56% to 59% were in clinical remission, depending on dose. About 85% of patients remained in the study through week 76.
Maria T. Abreu, MD, a gastroenterologist who directs the F. Widjaja Inflammatory Bowel Disease Institute at Cedars-Sinai in Los Angeles, presented the findings on behalf of her co-authors. The data were presented as an abstract and have not been peer-reviewed.
An oral approach to IL-23 inhibition
Developed by Johnson & Johnson, icotrokinra is an oral peptide that Dr. Abreu described as first-in-class. It blocks IL-23 from attaching to its receptor, unlike currently available IL-23 inhibitors, which are given by injection. In March 2026, the FDA approved it as Icotyde for patients aged 12 years and older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy for moderate to severe plaque psoriasis.
Earlier results from ANTHEM-UC showed that all three doses of icotrokinra improved clinical response rates at week 12, with the highest dose producing the greatest improvement in clinical remission. These benefits continued or increased through week 28. The long-term extension examined whether these benefits would continue with ongoing treatment.
Patients originally randomized to icotrokinra who were in clinical response at week 28, and whom investigators judged likely to benefit from continued therapy, could join the extension on the same dose. Of these, 48 received 100 mg of icotrokinra once daily, while 44 patients each received 200 mg or 400 mg once daily.
The researchers measured clinical response, clinical remission, remission without corticosteroids, endoscopic improvement, and symptomatic remission. These outcomes were planned in advance but considered exploratory, so no formal statistical tests were performed. Patients who discontinued treatment or had missing data were counted as nonresponders.
Results through week 76
Dr. Abreu reported that 81% of patients receiving 100 mg were in clinical response at week 76, compared with 73% in each of the 200-mg and 400-mg groups.
Clinical remission rates exceeded 50%, even among patients who had an inadequate response to or could not tolerate advanced therapies, and approached 60% among those without that history.
Dr. Abreu said patients without that history had higher response rates, a pattern that held at the 200-mg and 400-mg doses but not at 100 mg. These subgroup analyses were not prespecified.
Response rates did not increase with dose. Dr. Abreu noted that patients receiving the 400-mg dose were more likely to have extensive disease and to have had an inadequate response to two classes of advanced therapy, suggesting their disease may have been harder to treat.
Endoscopic improvement was seen in 64% to 68% of patients at week 76 and followed the same pattern by treatment history.
Dr. Abreu emphasized that the trial’s design allowed investigators to track patients’ improvement over a longer period. “You can see people continue to get better over a longer term,” she said during her presentation.
Dr. Abreu suggested that some patients who do not meet treatment goals by week 12 may benefit from staying on treatment longer. Some patients achieved remission of their symptoms as early as week 4, which she called “cool to see for an oral drug.”
Retention and safety
Dr. Abreu highlighted the high patient retention rate as an encouraging finding. “People voted with their feet,” she said.
Dr. Abreu said icotrokinra was “behaving like the other IL-23 antagonists” on safety. Through week 78, exposure-adjusted rates of serious adverse events and serious infections were numerically lower with icotrokinra than with placebo, although serious infections were rare, occurring in one patient receiving placebo and one receiving 100 mg. The most common adverse events with icotrokinra through week 78 were worsening of UC, upper respiratory tract infection, nasopharyngitis, headache, and arthralgia.
During the question-and-answer session, an attendee asked about corticosteroid use, noting that up to half of patients were taking steroids when the study began. Dr. Abreu explained that patients were required to begin reducing their steroid doses after week 12 but could use steroids as needed during the extension.
Of patients in clinical remission at week 76, 97% were also corticosteroid-free at that visit. Because steroid use was assessed only at week 76, some patients may have used steroids during the extension, Dr. Abreu said.
Clinical implications
Dr. Abreu concluded that icotrokinra has “potential benefit” as an oral treatment option for patients with moderate to severe UC. However, the extension enrolled only patients who were in clinical response at week 28, week 76 results were not compared with placebo, and week 76 endoscopies were read locally, without biopsies.
During the discussion, Dr. Abreu noted that improvements in rectal bleeding and stool frequency may occur before patients achieve clinical remission.
Once the drug is available, Dr. Abreu said, clinicians may be able to “pretty quickly see who’s going to have a really great response and who’s not going to have any response” and which patients may need a different treatment.
Icotrokinra is being evaluated in phase 3 trials for UC.
The study was supported by Johnson & Johnson. Five co-authors and the medical writer are Johnson & Johnson employees. Dr. Abreu reported speaking or advisory relationships with several pharmaceutical companies, including Johnson & Johnson.